Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:11:24 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:PSNL - PERSONALIS INC - https://www.personalis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PSNL - Q1.68.45·9.050.18.77-0.51-5.54,338.838,7257,3669.37  9.39  8.76511.38  2.826219:51:38Dec 1115 min RT 2¢

Recent Trades - Last 10 of 7366
Time ETExPriceChangeVolume
19:51:38Q8.87-0.415
19:34:09Q8.8658-0.41421
19:15:59Q8.87-0.415
17:41:24Q8.90-0.381,000
17:26:28Q8.95-0.33100
16:59:08Q9.00-0.288
16:46:27Q9.00-0.2825
16:30:27Q8.9188-0.3612100
16:10:04Q8.77-0.511
16:10:04Q8.77-0.511

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-11 09:00U:PSNLNews ReleaseNew Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
2025-11-18 16:01U:PSNLNews ReleasePersonalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
2025-11-10 09:00U:PSNLNews ReleasePersonalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
2025-11-04 16:01U:PSNLNews ReleasePersonalis Reports Third Quarter 2025 Financial Results
2025-10-21 16:01U:PSNLNews ReleasePersonalis to Announce Third Quarter 2025 Financial Results
2025-10-16 09:00U:PSNLNews ReleasePersonalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
2025-09-15 17:35U:PSNLNews ReleasePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-10 16:05U:PSNLNews ReleaseCATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
2025-09-03 16:05U:PSNLNews ReleasePersonalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
2025-08-27 16:01U:PSNLNews ReleasePersonalis to Participate in Upcoming Investor Conferences
2025-08-05 16:01U:PSNLNews ReleasePersonalis Reports Second Quarter 2025 Financial Results
2025-07-22 16:01U:PSNLNews ReleasePersonalis to Announce Second Quarter 2025 Financial Results
2025-07-18 16:00U:PSNLNews ReleasePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-07-09 16:00U:PSNLNews ReleasePersonalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
2025-06-03 16:00U:PSNLNews ReleasePersonalis' NeXT Personal(TM) Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
2025-06-02 16:00U:PSNLNews ReleaseNew Data Shows NeXT Personal(TM) Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
2025-05-22 06:00U:PSNLNews ReleasePersonalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
2025-05-14 16:01U:PSNLNews ReleasePersonalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
2025-05-06 16:01U:PSNLNews ReleasePersonalis Reports First Quarter 2025 Financial Results
2025-04-28 17:00U:PSNLNews ReleasePersonalis' NeXT Personal(TM) Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study